Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab.

Mitsukuni Suenaga, Nobuyuki Mizunuma, Kokoro Kobayashi, Eiji Shinozaki, Satoshi Matsusaka, Keisho Chin, Yasutoshi Kuboki, Takashi Ichimura, Masato Ozaka, Mariko Ogura, Yoshimasa Fujiwara, Kiyoshi Matsueda, Fumio Konishi, Kiyohiko Hatake

Journal: Medical oncology (Northwood, London, England) 2010;27(3):807-14

PMID: 19697164

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

Venous thromboembolism associated with use of a central venous access system is an urgent problem in patients treated with bevacizumab (bev). We investigated the effectiveness of Doppler ultrasound imaging (DUS) in the early detection of catheter-related thrombosis for avoidance of severe venous thromboembolism. Patients with metastatic colorectal cancer received either FOLFOX-4 + bev or FOLFIRI + bev. DUS was performed on the deep venous system for detection of thrombus formation during the initial cycle of treatment, followed by re-evaluation after the third cycle in patients with asymptomatic thrombus formation. All patients were followed up until treatment was interrupted. Median duration of follow-up was 484 days (range 72-574). Among 41 enrolled patients, curable symptomatic thrombosis occurred in one, and asymptomatic thrombosis in 21 (51.2%). Of 21 patients undergoing re-evaluation, thrombi remained without progression in 17 patients, and enlargement in 4 patients. In two of the patients in whom there was progression, pulmonary embolism occurred after the sixth cycle. In the asymptomatic group, no thrombi developed as far as the superior vena cava in any patient. In the cases of progression, thrombotic enlargement was observed in all the 4 patients, with decreased vascular flow in 2. Using DUS, we were able to detect asymptomatic thrombosis in the early cycles of treatment, indicating its potential in the monitoring of venous thrombi. In the event of an enlarging asymptomatic thrombosis developing into the superior vena cava along with decreased vascular flow, careful follow-up and appropriate anticoagulant therapy may be recommended without increased risk of bleeding.

Address: Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-10-6 Ariake, Koto-ku, Tokyo, 135-8550, Japan. [email protected]

DOI: 10.1007/s12032-009-9289-6

Link outs

Free resources

Medical:

https://medlineplus.gov/colorectalcancer.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Adenocarcinoma, Adolescent, Adult, Aged, Angiogenesis Inhibitors, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Anticoagulants, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Camptothecin, Catheterization, Central Venous, Colorectal Neoplasms, Disease Progression, Early Diagnosis, Female, Fluorouracil, Follow-Up Studies, Humans, Leucovorin, Male, Middle Aged, Organoplatinum Compounds, Prospective Studies, Pulmonary Embolism, Risk Factors, Thrombophilia, Ultrasonography, Doppler, Vena Cava, Superior, Venous Thromboembolism, Young Adult